HWMA
NBIX icon

Heritage Wealth Management (Arizona)’s Neurocrine Biosciences NBIX Stock Holding History

Heritage Wealth Management (Arizona)’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$3.34K Buy
28
+14
+100% +$1.64K ﹤0.01% 928
2022
Q3 		$1K Buy
+14
New +$1.42K ﹤0.01% 954

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Heritage Wealth Management (Arizona)'s NBIX Position: Q4 2022 in Review

Heritage Wealth Management (Arizona) increased its Neurocrine Biosciences (NBIX) stake by 100% in Q4 2022, buying an estimated $1.64K and bringing the position to 28 shares worth $3.34K. The position accounts for ﹤0.01% of the portfolio, ranked #928.

Heritage Wealth Management (Arizona) first reported a position in NBIX in Q3 2022 and has held it in 2 quarters since. 529 funds tracked by Wall St. Rank hold NBIX as of Q4 2022.

  • Heritage Wealth Management (Arizona) held 28 shares of Neurocrine Biosciences worth $3.34K as of Q4 2022.
  • Heritage Wealth Management (Arizona) bought 14 Neurocrine Biosciences shares in Q4 2022, an estimated $1.64K.
  • Neurocrine Biosciences made up ﹤0.01% of Heritage Wealth Management (Arizona)'s portfolio in Q4 2022, its #928 holding.
  • Heritage Wealth Management (Arizona) first reported a position in Neurocrine Biosciences in Q3 2022 and has held it in 2 quarters since.
  • 529 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2022.

Based on Heritage Wealth Management (Arizona)'s 13F filing for Q4 2022, filed 13 Feb 2023.